

USSN 09/808,867, filed March 15, 2001

Docket No. 1133279-0003

Page 3 of 22

Amendments to the Claims:

The listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently amended) A medical device comprising a coating, wherein the coating comprises ~~coated with~~ a therapeutically effective amount of at least one type or more antibodies and one or more layers of a matrix, and wherein the one or more antibodies is selected from the group consisting of antibodies, fragments thereof and combinations of the antibodies and fragments of antibody which react ~~reacts~~ with an endothelial cell surface antigen ~~and at least one layer of a matrix, wherein the matrix comprises a fullerene ranging from about C60 to about C100.~~
2. (Currently amended) The medical device of claim 1, wherein the matrix is layered onto the surface of the medical device and the one or more antibodies ~~antibody~~ is tethered covalently by a linker molecule to the matrix ~~at least one layer of the matrix coating the medical device.~~
3. (Cancelled)
4. (Original) The medical device of claim 1, wherein the antibody is a monoclonal antibody.
5. (Original) The medical device of claim 1, wherein the medical device is a stent.
6. (Withdrawn) The medical device of claim 1, wherein the medical device is a synthetic graft.
7. (Original) The medical device of claim 1, wherein the endothelial cell is a human cell.
8. (Original) The medical device of claim 4, wherein the monoclonal antibody reacts with endothelial cell surface antigen CD34.
9. (Original) The medical device of claim 4 or 8, wherein the monoclonal antibody comprises Fab or F(ab')₂ fragments.

USSN 09/808,867, filed March 15, 2001

Docket No. 1133279-0003

Page 4 of 22

10. (Withdrawn) A medical device coated with a therapeutically effective amount of at least one type of antibody which reacts with an endothelial cell antigen and at least one layer of a matrix, wherein the matrix comprises polyurethane, segmented polyurethane-urea/heparin, poly-L-lactic acid, cellulose ester, polyethylene glycol, collagen, laminin, heparin, fibrin, cellulose or carbon.
11. (Withdrawn) The medical device of claim 10, wherein the antibody is tethered covalently by a linker molecule to the last layer of the matrix coating the medical device.
12. (Withdrawn) The medical device of claim 10, wherein the antibody is a monoclonal antibody.
13. (Withdrawn) The medical device of claim 10, wherein the medical device is a stent.
14. (Withdrawn) The medical device of claim 10, wherein the medical device is a synthetic graft.
15. (Withdrawn) The medical device of claim 10, wherein the endothelial cell is a human cell.
16. (Withdrawn) The medical device of claim 12, wherein the monoclonal antibody reacts with endothelial cell surface antigen, CD34.
17. (Withdrawn) The medical device of claim 12 or 16, wherein the monoclonal antibody comprises Fab or F(ab')₂ fragments.
18. (Currently amended) A coating composition for rendering ~~coating~~ a medical device compatible for *in vivo* attachment and proliferation of cells on the surface thereof, wherein the coating composition comprises a matrix and a therapeutically effective amount of one or more antibodies, and wherein the one or more antibodies is selected from the group consisting of antibodies, fragments thereof and combinations of the antibodies and fragments which react ~~at least one type of antibody that reacts~~ with an endothelial cell surface antigen.

USSN 09/808,867, filed March 15, 2001
Docket No. 1133279-0003
Page 5 of 22

19. (Withdrawn) The composition of claim 18, wherein the matrix comprises polyurethane, segmented polyurethane-urea/heparin, poly-L-lactic acid, cellulose ester, polyethylene glycol, collagen, laminin, heparin, fibrin, cellulose or carbon.
20. (Currently amended) The coating composition of claim 18, wherein the matrix comprises a material selected from the group consisting of a fullerene ~~ranging from about C60 to about C100~~, polyurethane, segmented polyurethane-urea/heparin, poly-L-lactic acid, cellulose ester, polyethylene glycol, collagen, laminin, heparin, fibrin, cellulose, carbon, polytetrafluoroethylene, expanded polytetrafluoroethylene and mixtures thereof.
21. (Currently amended) The coating composition of claim 18 20, wherein the antibody is a monoclonal antibody.
22. (Currently amended) The coating composition of claim 18 21, wherein the endothelial cell is a human cell.
23. (Currently amended) The coating composition of claim 21, wherein the monoclonal antibody reacts with endothelial cell surface antigen, CD34.
24. (Currently amended) The coating composition of claim 21 or 23 22, wherein the monoclonal antibody comprises Fab or F(ab')₂ fragments.
25. (Currently amended) A method for rendering ~~coating~~ a medical device compatible for in vivo attachment and proliferation of cells on the surface thereof, comprising the steps of:
- (a) coating the a medical device with at least one or more layers ~~layer~~ of a matrix ~~comprising polyurethane, segmented polyurethane-urea/heparin, poly-L-lactic acid, cellulose ester, polyethylene glycol, collagen, laminin, heparin, fibrin, cellulose, fullerene or carbon; and~~

USSN 09/808,867, filed March 15, 2001
Docket No. 1133279-0003
Page 6 of 22

(h) adding to the matrix layer a therapeutically effective amount of at least one or more antibodies, wherein the one or more antibodies is selected from the group consisting of antibodies, fragments thereof and combinations of the antibodies and fragments which react type of antibody which reacts with an endothelial cell surface antigen ~~to the matrix coating the medical device.~~

26. (Withdrawn) The method of claim 25, wherein the antibody is noncovalently coated on the last layer of the matrix coating the medical device.

27. (Currently amended) The method of claim 25, wherein the antibody is tethered covalently by a linker molecule to the matrix ~~at least one layer of the matrix~~ coating the medical device.

28. (Canceled)

29. (Currently amended) A method of treating a mammal ~~mammals~~ for atherosclerosis comprising inserting ~~insertion of~~ a medical device into an artery of the mammal, wherein the medical device comprises a coating, wherein the coating comprises ~~is coated with~~ a therapeutically effective amount of one or more antibodies and at least one or more layers of ~~type of antibody which reacts with an endothelial cell surface antigen and a matrix, and wherein~~ the one or more antibodies is selected from the group consisting of antibodies, fragments thereof and combinations of the antibodies and fragments which react with an endothelial cell surface antigen ~~comprising a fullerene ranging from about C60 to C100.~~

30. (Original) The method of treatment of claim 29, wherein the antibody is a monoclonal antibody.

31. (Original) The method of treatment of claim 29, wherein the atherosclerosis is coronary artery atherosclerosis.

32. (Original) The method of treatment of claim 30, wherein the monoclonal antibody comprises Fab or F(ab')₂ fragments.

USSN 09/808,867, filed March 15, 2001
Docket No. 1133279-0003
Page 7 of 22

33. (Withdrawn) A method for treating mammals for atherosclerosis comprising insertion into an artery of a medical device, wherein the medical device is coated with at least one layer of a matrix comprising polyurethane, segmented polyurethane-urea/heparin, poly-L-lactic acid, cellulose ester, polyethylene glycol, collagen, laminin, heparin, fibrin, cellulose or carbon and a therapeutically effective amount of at least one type of antibody which reacts with an endothelial cell antigen.

34. (Withdrawn) The method of treatment of claim 33, wherein the antibody is a monoclonal antibody.

35. (Withdrawn) The method of treatment of claim 34, wherein the monoclonal antibody comprises Fab or F(ab')₂ fragments.

36. (Withdrawn) A method for treating mammals for obstruction of a vessel comprising insertion into a vessel of a medical device coated with at least one layer of a matrix comprising polyurethane, segmented polyurethane-urea/heparin, poly-L-lactic acid, cellulose ester, polyethylene glycol, collagen, laminin, heparin, fibrin, cellulose or carbon and a therapeutically effective amount of at least one type of antibody which reacts with an endothelial cell antigen.

37. (Withdrawn) The method of treatment of claim 36, wherein the antibody is a monoclonal antibody.

38. (Currently amended) A method for treating ~~a mammal~~ mammals for obstruction of a vessel comprising inserting a medical device into a vessel of the mammal, wherein the ~~a~~ medical device comprises a coating, wherein the coating comprises one or more antibodies and is coated with at least one or more layers layer of a matrix, and wherein the one or more antibodies is selected from the group consisting of antibodies, fragments thereof and combinations of the antibodies and fragments ~~comprising a fullerene ranging from about C60 to C100 and a therapeutically effective amount of at least one type of antibody~~ which react reacts with an endothelial cell surface antigen.

USSN 09/808,867, filed March 15, 2001
Docket No. 1133279-0003
Page 8 of 22

39. (Previously presented) The method of treatment of claim 38, wherein the vessel is an artery.

40. (Withdrawn) The method of treatment of claim 36 or 38, wherein the vessel is a vein.

41. (Currently amended) A medical device comprising ~~coated with at least one or more layers~~
~~layer~~ of a matrix ~~comprising a C60O fullerene~~, wherein the ~~at least one~~ matrix layer of the
~~matrix~~ is covalently attached to the medical device and the matrix comprises a C60O
fullerene.

42. (Withdrawn) The medical device of claim 41, wherein the first layer of the matrix is
noncovalently attached to the medical device.

43. (Cancelled)

44. (Cancelled)

45. (Original) The medical device of claim 41, wherein the medical device is a stent.

46. (Withdrawn) The medical device of claim 41, wherein the medical device is a synthetic
graft.

47. (Cancelled)

48. (Withdrawn) The medical device of claim 47, wherein the matrix is noncovalently attached
to the medical device.

49. (Cancelled)

50. (Cancelled)

51. (Withdrawn) The medical device of claim 47, wherein the medical device is a synthetic
graft.

USSN 09/808,867, filed March 15, 2001
Docket No. 1133279-0003
Page 9 of 22

52. (Withdrawn) A medical device coated with a therapeutically effective amount of at least one type of antibody which reacts with an endothelial cell antigen and at least one layer of a matrix, wherein the matrix comprises a naturally occurring material.

53. (Withdrawn) A medical device coated with a therapeutically effective amount of at least one type of antibody which reacts with an endothelial cell antigen and at least one layer of a matrix, wherein the matrix comprises a synthetic material.

54. (Withdrawn) A medical device coated with a therapeutically effective amount of at least one type of antibody which reacts with an endothelial cell antigen and at least one layer of a matrix, wherein the matrix comprises polytetrafluoroethylene.

55. (Withdrawn) A medical device coated with a therapeutically effective amount of at least one type of antibody which reacts with an endothelial cell antigen and at least one layer of a matrix, wherein the matrix comprises expanded polytetrafluoroethylene .

Claim 56-61 (cancelled)

62. (New) The medical device according to claim 1, wherein the matrix comprises a naturally occurring material or a synthetic material.

63. (New) The medical device according to claim 1, wherein the matrix comprises a material selected from the group consisting of a fullerene, polyurethane, segmented polyurethane-urea/heparin, poly-L-lactic acid, cellulose ester, polyethylene glycol, collagen, laminin, heparin, fibrin, cellulose, carbon, polytetrafluoroethylene, expanded polytetrafluoroethylene and mixtures thereof.

64. (New) The medical device according to claim 63, wherein the fullerene ranges from about C60 to about C100.

65. (New) The medical device according to claim 63, wherein the fullerene is C60O.

USSN 09/808,867, filed March 15, 2001

Docket No. 1133279-0003

Page 10 of 22

66. (New) The coating composition according to claim 18, wherein the matrix comprises a naturally occurring material or a synthetic material.
67. (New) The coating composition according to claim 20, wherein the fullerene ranges from about C60 to about C100.
68. (New) The coating composition according to claim 20, wherein the fullerene is C60O.
69. (New) The method according to claim 25, wherein the matrix comprises a naturally occurring material or a synthetic material.
70. (New) The method according to claim 25, wherein the matrix comprises a material selected from the group consisting of a fullerene, polyurethane, segmented polyurethane-urea/heparin, poly-L-lactic acid, cellulose ester, polyethylene glycol, collagen, laminin, heparin, fibrin, cellulose, carbon, polytetrafluoroethylene, expanded polytetrafluoroethylene and mixtures thereof.
71. (New) The method according to claim 70, wherein the fullerene ranges from about C60 to about C100.
72. (New) The method according to claim 70, wherein the fullerene is C60O.
73. (New) The method according to claim 29 or 38, wherein the matrix comprises a naturally occurring material or a synthetic material.
74. (New) The method according to claim 29 or 38, wherein the matrix comprises a material selected from the group consisting of a fullerene, polyurethane, segmented polyurethane-urea/heparin, poly-L-lactic acid, cellulose ester, polyethylene glycol, collagen, laminin, heparin, fibrin, cellulose, carbon, polytetrafluoroethylene, expanded polytetrafluoroethylene and mixtures thereof.

FROM W&C LLP 19TH FL.

(WED) 12. 1' 04 4:50/ST. 4:46/NO. 4260454805 P 12

USSN 09/808,867, filed March 15, 2001

Docket No. 1133279-0003

Page 11 of 22

75. (New) The method according to claim 74, wherein the fullerene ranges from about C60 to about C100.

76. (New) The method according to claim 74, wherein the fullerene is C60O.